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wireless data transfer to the PC. Feasibility studies have 
been performed on DICOM images for meningioma and 
glioma brain tumors and neuroendocrine tumors (NET). The 
technique is in validation phase by testing it on “ex-vivo” 
specimen of patients affected by meningioma. 
Results: As first application we are investigating brain 
tumors. The goal is to apply the technique to glioma, but 
the first study case is meningioma being an efficient tracer 
(90Y-DOTATOC) already available for it. Preclinical tests 
and Monte Carlo simulations have estimated that in the 
case of meningioma to identify in 1s a residual of 0.1ml a 
radio-pharmaceutical activity of about 3MBq/kg must be 
administered to patient [2]. Similar studies were extended 
to NETs[3] Ex-vivo tests on meningioma showed excellent 
agreement between experimental and expected rates for 
lesions and healthy tissues: e.g. the bulk tumor showed 
signals of ~100cps, 0.2 ml residuals signals of ~40cps and 
healthy tissues of less than 5cps. 
Furthermore, exposure measurements confirmed the low 
level of radioactivity in the surgical environment (<1µSv/h 
at 10cm from patient abdomen). 
Conclusions: A very promising technique for RGS is under 
development. The low background would allow to extend 
RGS also to cases with a large uptake of nearby healthy 
organs where the established approach with γ radiation 
suffers due to the non-negligible background. 
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Purpose: Folate-receptor (FR)-targeted radioconjugates are 
promising for the imaging of a wide variety of tumor types 
[1]. So far, a number of folic acid conjugates have been 
developed for labeling with radiometals (e.g. 99mTc, 111In, 
68Ga) for SPECT and PET imaging [2]. The aim of this study 
was to synthesize a folate conjugate with an albumin-binding 
entity, which is known to increase the conjugate’s blood 
circulation time, and a NODAGA-chelator for 64Cu-labeling 
and [3]. 64Cu is a promising PET radionuclide for rf42 due to 
its excellent β+-energy (Eβ+=278 keV) and its reasonably long 
half-life (T1/2 = 12.7 h) [4]. The 64Cu-NODAGA-folate (64Cu-
rf42) was investigated in vitro and in vivo using mice bearing 
FR-positive tumor xenografts. 
Materials/methods: 64Cu was produced via the irradiation of, 
and subsequent chemical separation from, a Ni target at the 
research cyclotron at PSI. The synthesis of the NODAGA-
folate conjugate (rf42) was carried out in eight steps and the 
resulting product was characterized by HPLC, MS and NMR. 
The radioconjugate was prepared by incubation of rf42 with 
64CuCl2 in a mixture of HCl/Na-acetate (pH ~5.5) at 45°C for 
15 min. 64Cu-rf42 was investigated regarding its in vitro 
stability in PBS (pH 7.4) and in human plasma. FR-positive KB 
tumor cells were used for in vitro experiments. 
Biodistribution studies were carried out in KB tumor-bearing 
nude mice at 2 h, 4 h and 24 h post injection (p.i.) of 64Cu-
rf42. A small-animal scanner (Genisys8) was used for the 
PET/CT imaging studies 
Results: rf42 was synthesized with an overall yield of 5% and 
95% purity. The radiochemical purity of 64Cu-rf42 was >99% at 
a specific activity of 10 MBq/nmol. 64Cu-rf42 was stable 
(>95%) over a period of 24 h in buffer and plasma. Cell 
internalization studies showed high uptake of 64Cu-rf42, while 
co-incubation of cells with excess folic acid to block FRs 
reduced the uptake to less than 1%. In vivo, high 
accumulation of radioactivity was found in KB tumors (13.36 
± 0.82% IA/g) 2 h after injection of 64Cu-rf42. As a 
consequence of the enhanced blood circulation time of 64Cu-
rf42, due to its albumin-binding properties, the tumor uptake 
increased over time (16.20 ± 3.58% IA/g, 24 h p.i.). Relevant 
uptake of 64Cu-rf42 was also found in the kidneys, which also 
express the FR. This resulted in a tumor-to-kidney ratio of 
0.55 ± 0.11 at 24 h p.i. In non-targeted tissues undesired 
accumulation of radioactivity decreased over time. PET/CT 
imaging studies allowed excellent visualization of tumor 
xenografts up to 60 h p.i. of 64Cu-rf42.   
Conclusion: The novel folate-radioconjugate, 64Cu-rf42, was 
readily prepared and showed FR-specific accumulation in 
vitro and in vivo. The half-life of 64Cu is well suited to the 
enhanced circulation time of this novel albumin-binding 
conjugate. Based on the excellent PET images obtained from 
visualizing tumors in mice, 64Cu-rf42 may have the potential 
for future application in the clinics for diagnosis of FR-
positive tumors and monitoring tumor response after therapy. 
 
Keywords: 64Cu, tumor imaging, folate-receptor  
 
References: 
[1] Sega et al. 2008, Cancer Metastasis Rev 4:655-664. 
[2] Müller et al. 2011, J Nucl Med 1 :1-4. 
[3] Müller et al. 2013, J Nucl Med 1 :124-131. 
[4] Smith et al. 2004, J Inorg Biochem 98 :1874-1901. 
 
83 
Geant4 coupled with Comsol heat transfer simulations to 
determine correction factors of a novel micro-calorimeter 
K. Fathi1, 5, S. Galer1, H. Palmans1, 2, K. Kirkby3, A. Nisbet4, 5 
1Acoustic and Ionising Radiation, National Physical 
Laboratory, Teddington 
2Medical Physics, MedAustron, Austria 
3Institute of Cancer Sciences, Medical Health Sciences, 
Manchester 
4Medical Physics, Royal Surrey County Hospital, Guildford 
5Physics, University of Surrey, Guildford 
 
High uncertainty in the Relative Biological Effectiveness 
(RBE) values of particle therapy beam, which are used in 
combination with the quantity absorbed dose in 
radiotherapy, together with the increase in the number of 
particle therapy centres worldwide (58 in operation, 51 
proposed) necessitate a better understating of the biological 
effect of such modalities. The present novel study is part of 
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performance testing and development of a micro-calorimeter 
based on Superconducting QUantum Interference Devices 
(SQUIDs) (1). Unlike other microdosimetric detectors that are 
used for investigating the energy distribution, this detector 
provides a direct measurement of energy deposition at the 
micrometer scale, that can be used to improve our 
understanding of biological effects in particle therapy 
application, radiation protection and environmental 
dosimetry. Temperature rises of less than 1µK are detectible 
and when combined with the low specific heat capacity of 
the absorber at cryogenic temperature, extremely high 
energy deposition sensitivity of approximately 0.4 eV can be 
achieved (2).  
The detector consists of 3 layers: a tissue equivalent (TE) 
absorber, a superconducting absorber and a silicon substrate. 
Ideally all energy would be absorbed in the TE absorber and 
heat rise in the superconducting layer would arise due to 
heat conduction from the TE layer. However, in practice 
direct particle absorption occurs in all 3 layers and must be 
corrected for. 
To investigate the thermal behavior within the detector, and 
quantify any possible correction, particle tracks were 
simulated employing Geant4 (v9.6) Monte Carlo simulations. 
The track information was then passed to the COMSOL 
Multiphysics (Finite Element Method) software. The 3D heat 
transfer within each layer was then evaluated in a time-
dependent model. For a statistically reliable outcome, the 
simulations had to be repeated for a large number of 
particles. An automated system has been developed that 
couples Geant4 Monte Carlo output to COMSOL for 
determining the expected distribution of proton tracks and 
their thermal contribution within the detector.  
Preliminary results of a 3.8 MeV proton beam showed that 
the detector reaches the equilibrium state after 8 ns.  It is 
estimated that 20% of the temperature rise in the 
superconducting absorber is due to heat conduction from the 
adjacent absorber which needs to be corrected for. The 
simulations were repeated for proton beams with energies of 
2, 10, 62 and 230 MeV. 
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Purpose: Nowadays, during the evaluation process of patient 
treatment plans in radiotherapy, the plan robustness is 
typically not taken into account. This evaluation of 
treatment plans can be improved if a user friendly and 
efficient tool to assess the robustness of the treatment plan 
is provided. Thus, the aim of this work is to develop tools and 
methods to quantify and visualize the robustness for 
treatment plans including random and systematic patient 
setup uncertainties. 
Materials and Methods: A setup error phase-space including 
systematic and random setup errors for translation and 
rotation is explored to determine the treatment plan 
robustness. For this purpose a robustness-map is created 
based on user-defined criteria defining the robustness for the 
treatment plan considered. These criteria subdivide the 
robustness-map for the setup error phase-space into a region 
compatible with these criteria and into another one that is 
not. Several different approaches were implemented to 
quantify the plan robustness. One approach transforms the 
optimized dose distribution relatively to the patient 
geometry and, thus, dosimetric parameters or DVHs can be 
quickly estimated, but are limited with respect to accuracy. 
Hence, approaches using further dose calculations for the 
setup error phase space are needed to achieve reliable 
conclusions of the robustness. For this purpose, additional 
dose calculations using a different resolution of the setup 
error phase-space are performed guided by the robustness-
map achieved using the dose-transformation approach. The 
intermediate dose distributions are determined by nearest 
neighbor or triangular interpolation. 
Results: A graphical user interface based on QT version 5.3.1 
was developed to calculate and visualize robustness-maps. 
These robustness-maps allow treatment plan evaluation by 
analyzing the corresponding dose-differences and DVHs. 
Additionally, correlations of all quantities can be displayed 
such that the user is able to efficiently view the data by 
scrolling through the setup error phase-space. The creation 
of robustness-maps is useful to assess and compare the 
robustness of different treatment plans and was successfully 
applied to plans covering different tumor-sites. For the cases 
investigated in this work, differences in DVH parameters 
using the different approaches are within 5%. 
Conclusions: The developed tool for visualization and analysis 
of robustness-maps is an easy and efficient way to compare 
the robustness of treatment plans. Moreover, clinical 
tolerance and action levels for patient setup can be 
determined in order to keep specified dosimetric parameters 
within a certain limit. This work was supported by Varian 
Medical Systems. 
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Purpose: In this paper we report the preliminary results of 
clinical use of organ motion mitigation strategies in the 
treatment of moving target with active scanned carbon ion 
beams. 
Material and methods: Since September 2014 25 patients 
with tumors located in the upper abdomen and chest were 
treated with active scanned carbon ion beams. 
Patients were affected by pancreatic adenocarcinoma, HCC, 
biliary tract cancers and sarcoma of the spine 
retroperitoneum and heart. Tight thermoplastic mask was 
selected as the optimal abdominal compression device. 4D CT 
scan with retrospective reconstruction, with phase signal 
obtained with Anzai system (Anzai Medical CO., LTD), was 
employed for planning.  Automatic assignment of raw data to 
respiratory phases was checked and, if necessary, modified 
by the medical physicist.  Planning was performed using end 
expiration phase. Planning CT scan were visually checked for 
motion artifacts. Contouring was performed on end 
expiration phase and on the adjacent 30% expiration and 30% 
inspiration phases. Beam entrance was selected in order to 
avoid the bowel in the entrance channel. The lung diaphragm 
interface was contoured in the different respiratory phases 
and beam angles were chosen to avoid passing tangential to 
the lung diaphragm ITV. IMPT was used for plan optimization. 
Plans were recalculated in adjacent phases and if DVHs were 
degraded in an unacceptable way they were modified 
iteratively. Weekly verification 4D CT scans were performed 
